Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance of 14C-RAY1225 in healthy Chinese participants
NCT07460284Phase 1Not yet recruiting
- Sponsor
- Raynovent Biotech
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RAY1225 in obesity and type 2 diabetes mellitus (T2DM), sponsored by Raynovent Biotech. Primary endpoints: Total radioactivity recovery and cumulative recovery in urine and feces at 60 days and Radioactivity of each metabolite in urine and feces and circulating metabolites in plasma at 60 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
RAY1225
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07460284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460284.